<DOC>
	<DOC>NCT01332383</DOC>
	<brief_summary>To investigate the long-term safety and efficacy of AMERGE (naratriptan hydrochloride) on Japanese patients with migraine headache in clinical setting</brief_summary>
	<brief_title>Special Drug Use Investigation for AMERGEÂ® Tablet (Long-term)</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naratriptan</mesh_term>
	<criteria>Must use AMERGE for the first time Patients with hypersensitivity to naratriptan or any of the components. Patients with history, symptoms, or signs of myocardial infarction, ischemic cardiac or angina inversa Patients with history of cerebral vascular disturbance or transient ischaemic attack Patients with peripheral vascular syndromes Patients with uncontrolled hypertension Patients with severe renal or hepatic impairment Patients using treatment with another 5HT1 agonist, an ergotaminecontaining or ergottype medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>